MEP technology in a daily serum and cream

June 17, 2019

This is a sidebar to the story "

This is a sidebar to the story "A solution for estrogen-deficient skin."

“MEP is the active ingredient in a new product called Emepelle,” says Diane Berson, M.D. “It has two components: a serum that is used in the morning and a cream which is used at night,” she says.

Both products are packed with additional ingredients, including antioxidants, niacinamide, vitamins C and E, peptides and/or retinol.

And that’s no accident.

According to Elliott Milstein, Senior Vice President of Product Innovation at Ferndale Pharma Group, the company decided to deliver MEP in combination with other key skin care ingredients to simplify and economize the daily routine.

So instead of adding yet another product to the daily skincare lineup, “The [Empelle] cream has retinoids and peptides and the serum has vitamin C and antioxidants to potentially replace other AM and PM products. This will significantly reduce the incremental cost of using the Emepelle products, says Milstein.

Of note, to get continued results from the MEP technology, patients will need to use it indefinitely.

“If the patient has estrogen deficient skin, they really need to apply an MEP product in both the AM and PM. But if you have a sensitivity to retinol, you could use the serum twice a day,” says Milstein.

Alternatively, women could simply use one or the other product just once a day. However, Milstein points out, “There is a greater effect if the ER activator is present in the skin 24 hours a day.”

“If you look at the ingredients, the serum contains antioxidants, niacinamide, vitamins C and E and phloretin. The nighttime cream contains a higher percentage of niacinamide - which, besides being an antioxidant, also helps restore the barrier - and peptides and retinol, which we always tell patients to use to stimulate collagen and help reverse the signs of aging,” says Dr. Berson.

Disclosures:

Dr. Berson has received research funding from Ferndale Laboratories. Mr. Milstein is Senior Vice President of Product Innovation at Ferndale Pharma Group.

download issueDownload Issue : Dermatology Times, July 2019 (Vol. 40, No. 7)